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Abstract
Background: We do not yet know how to use blood glucose self-monitoring (BGSM) most effectively in the self-
management of type 2 diabetes treated with oral medication. Training in monitoring may be most effective in improving
glycaemic control and well being when results are linked to behavioural change.
Methods/design: DiGEM is a three arm randomised parallel group trial set in UK general practices. A total of 450
patients with type 2 diabetes managed with lifestyle or oral glucose lowering medication are included. The trial compares
effectiveness of three strategies for monitoring glycaemic control over 12 months (1) a control group with three monthly
HbA1c measurements; interpreted with nurse-practitioner; (2) A self-testing of blood glucose group; interpreted with
nurse- practitioner to inform adjustment of medication in addition to 1; (3) A self-monitoring of blood glucose group
with personal use of results to interpret results in relation to lifestyle changes in addition to 1 and 2.
The trial has an 80% power at a 5% level of significance to detect a difference in change in the primary outcome, HbA1c
of 0.5% between groups, allowing for an attrition rate of 10%. Secondary outcome measures include health service costs,
well-being, and the intervention effect in sub-groups defined by duration of diabetes, current management, health status
at baseline and co-morbidity. A mediation analysis will explore the extent to which changes in beliefs about self-
management of diabetes between experimental groups leads to changes in outcomes in accordance with the Common
Sense Model of illness. The study is open and has recruited more than half the target sample. The trial is expected to
report in 2007.
Discussion: The DiGEM intervention and trial design address weaknesses of previous research by use of a sample size
with power to detect a clinically significant change in HbA1c, recruitment from a well-characterised primary care
population, definition of feasible monitoring and behaviour change strategies based on psychological theory and evidence,
and measures along the hypothesised causal path from cognitions to behaviours and disease and well being related
outcomes. The trial will provide evidence to support, focus or discourage use of specific BGSM strategies.
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Diabetes is now a major public health problem. The
number of people with diabetes is estimated to reach 330
million by 2030 [1]. There is a high burden from the dis-
ease: people with diabetes have an increased two to four
fold risk of stroke and heart disease compared to the gen-
eral population, and increased incidence of retinopathy,
peripheral nerve damage and renal problems.
There is now strong evidence for the effectiveness of tight
glycaemic control in reducing complications among peo-
ple with diabetes [2]. However, the evidence with which
to translate these research findings into guidance for deliv-
ery of health care is lacking [3]. In particular, efforts to
promote self management of diabetes have shown limited
and transient success in improving HbA1c levels [4].
Blood glucose self-monitoring (BGSM) is a technology
that is frequently incorporated into self-management
interventions, but has only been separately evaluated in a
limited number of trials. Despite the lack of evidence,
guidance is given both supporting and discouraging the
use of BGSM.
BGSM was used to underpin insulin dose adjustment in
the Diabetes Control and Complications Trial among
people with type 1 diabetes, which clearly demonstrated
the efficacy of glycaemic control in reducing diabetic com-
plications. However, neither the rationale for BGSM nor
its efficacy or effectiveness among people with type 2 dia-
betes is clear. Yet BGSM is now widely accepted as part of
management of people with type 2 diabetes [5,6], and the
costs associated with its use are rising rapidly [7]. Further
trials are required to evaluate the benefit and cost-effec-
tiveness of this technology and its place in the self man-
agement of people with type 2 diabetes.
Target population
People with type 2 diabetes are at risk from a range of
macrovascular and microvascular diabetic complications.
Large trials have confirmed the effectiveness of intensive
glycaemic control at reducing these complications [2].
Tight glycaemic control can be achieved through lifestyle
change and medications. The target population will com-
prise the majority of patients on the average practice list
with diabetes; we will focus on those patients within 5–10
yrs of diagnosis who are still comparatively healthy, of
average age around 55–65 y, and managed on a range of
medications and lifestyle advice. The exclusion of those
with regular experience of BGSM will be required to avoid
randomising them to a group not using meters.
Limitations of previous research
Limited evidence for effectiveness from non randomised studies
A recent qualitative study has suggested that self-monitor-
ing may be an important factor in helping people achieve
a better understanding of their condition [8]. However,
one study carried out in outpatient and general practi-
tioner clinics in Italy found that increased frequency of
monitoring was only associated with improved metabolic
control in people able to adjust insulin doses [9]. A pop-
ulation study in the United States also found little rela-
tionship between testing frequency and HbA1c value [10].
By contrast, another large study using a cohort design car-
ried out in a group model health maintenance organisa-
tion in California has suggested better glycaemic control
among type 2 diabetes patients when using a BGSM com-
pared to no use. Although attempts were made to control
for differences between groups, the possibility of con-
founding between attitudes to self-care and use of BGSM
cannot be excluded [11].
Limitations of and lack of evidence of effectiveness from randomised 
trials
Three systematic reviews have provided no evidence that
self monitoring is effective in improving glycaemic con-
trol for people with type 2 diabetes when compared to
urine testing and measurement of glycosylated haemo-
globin (HbA1c) [12-14]. The majority of trials identified
in these reviews have been carried out in small groups of
people. Participants were not recruited from representa-
tive populations in the community and the strategies for
use of the results from BGSM were not clearly defined.
Two more recent studies, set both in hospitals and a fam-
ily practice setting have adopted a more structured
approach to relating blood glucose measurements to sub-
sequent management decisions, but both trials have only
published an analysis of people adhering to use of BGSM
[15,16].
Research on mediators of effect not investigated in trials
There are a small number of studies that offer some
insight into how BGSM might lead to improved blood
glucose control among people with type 2 diabetes. BGSM
may be helpful in the titration of therapy by either
patients or by practitioners or both, but whether regular
monitoring is more effective than periodic measurement
of HbA1c is unknown. Evidence from qualitative studies
with patients suggests that awareness of fluctuations in
blood glucose levels may promote adherence to self-care
behaviours, including medication taking, diet and physi-
cal activity in selected patients [8,17].
There is increasing work in the area of diabetes self-man-
agement that uses psychological theory to guide interven-
tion and measurement of the processes of behaviour
change. One approach, the Common Sense Model (CSM)
[18], proposes that how people understanding threats to
their health in central in determining efforts to minimise
these health threats. For instance, if people with type 2
diabetes do not believe that physical activity affects theirPage 2 of 8
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active to control their condition. Beliefs about illness can
be categorised in terms of whether they relate to symp-
toms/ identity, cause, consequences, time lines, and con-
trol/ cure [18]. In support of the CSM, previous work has
shown that beliefs about the consequences and controlla-
bility of diabetes, and the perceived effectiveness of treat-
ment [19-21], predict patient adherence to recommended
lifestyle management. Further, an intervention with myo-
cardial infarction patients based on the CSM successfully
managed to alter unhelpful beliefs, and led to faster return
to work and fewer symptoms in the intervention group
[23]. Further work using this approach to guide interven-
tion and measures with people with type 2 diabetes may
inform understanding of the potential mechanisms
through which BGSM may improve health.
Limitations of previous interventions
Technology
The majority of previous trials have used reflectance
meters rather than biosensor technology. The older
meters required larger quantities of blood and took longer
to produce a reading than current systems. Although
when used correctly the older meters provided reliable
information, in practice their accuracy, usability and so
potential impact was limited and may have formed a bar-
rier to their effectiveness without high levels of
motivation.
Strategy for use of meters
Only one identified randomised trial specified the
approach used with patients to support their interpreta-
tion of test results [15]. Patients were told that using the
meter and keeping records in a diary would provide infor-
mation that would help them adjust their diet and life-
style. A defined counselling algorithm was used to help
ensure uniformity of delivery, but the extent to which the
counselling helped patients relate the results to behaviour
change is unclear. However, the impact of the interven-
tion on self-perception, self-reflection and beliefs are not
reported. The only published results of the study are from
a per-protocol analysis rather than an intention to treat
analysis [15]. Therefore, further work in which the inter-
vention includes linking decision making to behaviour
change is required.
Quality assurance
Previous trials have not specified the efforts made to mon-
itor delivery of interventions. These include both the proc-
ess of attempting to ensure that participants understand
the techniques being used, and that efforts are made to
ensure that the intervention is delivered as per protocol,
and that there is adequate separation from the compari-
son groups in the intervention delivery.
DiGEM Objectives
Primary objective
Our primary objective is to determine whether HbA1c is
significantly lower in patients with type 2 diabetes allo-
cated to each of two intervention groups (both receiving
training in the techniques of blood glucose self-monitor-
ing, but with one additionally receiving training in the
interpretation and application of the results to diet, phys-
ical activity and medication adherence) compared to
patients allocated to a control group (receiving standard-
ised usual care involving intermittent measurement of
HbA1c by health professionals).
Secondary objectives
Secondary objectives are:
(i) To compare well-being, satisfaction, health service use
and economic cost between allocated groups.
(ii) To conduct an exploratory analysis of changes in
mean HbA1c between regimens among sub-groups
defined by duration of diabetes, current management,
self-reported health status and co-morbidity.
(iii) To test how self-monitoring influences beliefs and
behaviour using measures chosen on the basis of theoret-
ical models of behaviour change.
Methods/design
DiGEM is a four-year study with an open, randomised
controlled pragmatic parallel group trial design (Figure 1)
with sequential recruitment from two centres. The trial is
managed from the Department of Primary Health Care,
University of Oxford following NHS R&D Health Tech-
nology Assessment Programme guidelines. The study pro-
tocol was approved by the Oxfordshire B Research Ethics
Committee.
The study design is shown in Figure 1. Participants are ran-
domised to three groups consisting of
(i) a control group receiving standardised usual care and
three monthly measurement of HbA1c,
(ii) a self-testing group who, in addition to the above, are
carrying out blood glucose self testing with the results
interpreted by the study nurse,
(iii) a self monitoring group who, in addition to both of
the above, are given support in interpreting and applying
the results of blood testing to enhance motivation and
maintain adherence to diet physical activity and medica-
tion regimens.Page 3 of 8
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education and training appropriate for their group, with
follow up to maintain the interventions at four, 13, 26,
and 39 weeks with a final assessment at 52 weeks.
Setting and recruitment
Non-insulin using patients with type 2 diabetes have been
recruited from general practices in Oxfordshire and are
being recruited from South Yorkshire to take part in the
study. The 48 recruited practices represent a geographical
spread of rural/suburban centres and cover a wide socio-
economic range of patients. The mean number of patients
recruited in the 24 practices in Oxfordshire was 10.2,
standard deviation (SD) 5.6.
Patients suitable for trial inclusion are identified from
practice generated computer lists. Eligible patients are sent
an invitation to participate signed by their general practi-
tioner accompanied by an information sheet and a reply
paid envelope to facilitate response. One further letter is
sent if no response is received in one month.
Study population: inclusion and exclusion criteria
Inclusion criteria are type 2 diabetes, aged 25 years or
more at diagnosis, managed with lifestyle or oral hypogly-
caemic agents, independent for activities of daily living.
Exclusion criteria are use of blood glucose monitor twice
a week or more often over the previous three months, cur-
rent use of insulin, co-morbidity or limited life expectancy
that would make intensive glycaemic control inappropri-
ate, last clinic HbA1c or HbA1c at the assessment visit less
than 6.2%, or unable to follow trial procedures.
Randomisation
Participants are randomly allocated to one of the three
groups using a partial minimisation procedure to adjust
the randomisation probabilities between groups to bal-
ance important covariates including duration of diabetes,
HbA1c, and prior medication using a computer pro-
gramme (Minim, http://www.sghms.ac.uk/depts/phs/
guide/randser.htm).
Baseline measures and follow up
The primary outcome measure is change in HbA1c
between the baseline measurement at the assessment visit
and 12-month visit. Secondary outcome measures include
change in systolic and diastolic blood pressure, weight,
serum cholesterol and HDL, self-reported smoking status,
dietary intake and physical activity (the Diabetes Self Care
Activities Questionnaire) [22], medication adherence
(The Medication Adherence Rating Scale) [23], and the
scores in the Diabetes Treatment Satisfaction Question-
naire [24], and the Well-being Questionnaire (12 item)
[25].
Consort diagram showing planned study numbersFigure 1
Consort diagram showing planned study numbers.Page 4 of 8
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using the Illness perceptions Questionnaire [26], Beliefs
about Medicines Questionnaire [27], and a questionnaire
developed for the study about the effectiveness of changes
in eating and physical activity on the course of diabetes,
and attitudes to blood glucose self-monitoring. Table 1
summarises the measures and their timing.
Blood glucose monitoring resources are measured by
counting recorded entries in diaries. Medication use, epi-
sodes of hospitalisation and their duration will be noted
and non-hospital health care resource use will be recorded
by a questionnaire administered to all patients at each
visit.
Trial procedures
Assessment
Participant eligibility for the study and willingness to be
randomised to a group in which they might be required to
test their own blood glucose six times a week or more is
confirmed at the assessment visit. Following consent,
beliefs about diabetes, the role of eating, physical activity
and medication are discussed with all participants. A goal
setting approach to lifestyle change is introduced and con-
tinued in subsequent visits. Baseline blood tests and
clinical measurements are taken and questionnaires com-
pleted at this visit.
Following the assessment visit and confirmation of eligi-
bility on the basis of HbA1c measurement, patients are
randomised to one of three groups: control group, self-
testing and self-monitoring.
Post-randomisation
At a visit two weeks after the assessment visit participants
receive training and education appropriate to their allo-
cated study group. The control group receives 3-monthly
HbA1c measurements and identifies behavioural goals to
improve glycaemic control. The self-testing group, in
addition, is asked to use a blood glucose meter to record
Table 1: Study measures
Measures Baseline 3 months 6 months 9 months 12 months
Questionnaire measures:
Illness perceptions questionnaire [26]
Well-being questionnaire 12-item [25]
Beliefs about medicines questionnaire
Medication Adherence Report scale
Beliefs about physical activity and eating +
Beliefs about blood glucose monitoring +
Beliefs about using a blood glucose monitor+
Occupation and social class
Physiological measures
HbA1c
Blood pressure
Weight, height
Total and HDL cholesterol
Costs
Use of medical services
Costs of medication
Costs of delivering intervention
? ?
? ?
? ?
? ?
? ?
? ?
? ?
?
?
? ?
? ?
? ?
? ?
? ? ? ? ?
? ?
?Page 5 of 8
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two days during the week. Treatment targets of fasting and
pre-meal levels of 4–6 mmol/l and post meal levels of 6 to
8 mmol/l and advice about using these readings to iden-
tify high (>15 mmol/l) and low (<4 mmol/l) blood glu-
cose readings are given. The self-monitoring group, in
addition, is provided with training and support to encour-
age interpretation of readings and application to goals for
lifestyle change based on the CSM in order to reach treat-
ment targets.
Follow up visits
Subsequent follow up includes a telephone call 2 weeks
after randomisation (after the post-randomisation visit
rather than randomisation), and further visits at 4, 13, 26
and 39 weeks. The follow up visits differ according to the
allocated group. Those allocated to the control group have
a HbA1c measure two weeks before their scheduled visit
in order for their glycaemic control to be discussed. The
two groups using a meter are managed on the results of
their blood glucose self-monitoring. The GP is notified of
all HbA1c results and asked to consider changes in medi-
cation in line with the National Institute for Clinical
Excellence diabetes guidelines. The GP is also notified if
blood glucose readings are consistently above 15 mmol/l.
Study measures (see Table 1 and Figure 1)
Baseline self-report measures and measures of belief are
completed at the assessment visit. Baseline biochemical
measures and clinical measurements are also made.
Repeated measurements are made at the 52-week follow
up visit. Data on adverse reactions or complications are
collected at each study visit along with information about
use of medication and health services.
Quality assurance and fidelity of interventions
Patients are supplied with a blood glucose meter cali-
brated to provide plasma equivalent results. Meters are
checked at the beginning of the study and at 26 weeks by
study nurses with a test aliquot.
A script outlining the topics to be covered, and explana-
tion of the theoretical basis of the intervention are used to
support the nurses in their adherence to study protocol.
Study nurses attended a six day phased course in psycho-
logical theory, behaviour change techniques and skills
training in the intervention. Additional measures to
ensure fidelity include self-review of taped interventions
by the study nurses and external review by a researcher
using a checklist to ensure delivery of the intervention
according to protocol. Prompts built into the patient dia-
ries help participants adhere to their allocated group
intervention.
Statistical aspects
In the absence of data relating to change in HbA1c we
have calculated sample size conservatively based on the
absolute level of HbA1c at follow up. We set out to detect
a difference in HbA1c of 0.5% between any two groups. At
the outset we estimated the SD of HbA1c as 1.5, based on
data from the UKPDS. In practice, the SD of baseline
HbA1c among the 245 patients recruited in Oxford was
0.9, but we assumed that the SD among additional
patients recruited elsewhere could be as high as 1.5. With
205 further patients, the overall SD would be 1.2, and
there would be 150 patients in each group (135 allowing
for 10% attrition). These numbers would give 93% power
to detect a difference of 0.5% in HbA1c between any two
trial groups (2-tailed alpha = 0.05). Figure 1 gives esti-
mates of likely numbers in each group and attrition.
We propose to conduct a single analysis of main trial end-
points at the end of the study. The proposed intention to
treat analysis will compare mean levels of HbA1c at follow
up between the three study groups, with baseline HbA1c
as a covariate, using analysis of covariance. Post-hoc t-
tests between groups will be conducted in the event of a
statistically significant result. Subsequent analysis will
include comparing the two intervention groups against
the control group.
We will estimate the intervention effect in sub-groups
defined by duration of diabetes (above or below median
duration), current management (oral hypoglycaemic dugs
or dietary management only), health status at baseline
(above or below median EQ-5D score) and co-morbidity
(presence or absence of diabetes related complications).
We will also explore the extent to which the measures of
beliefs included in the study can explain changes in
behaviour; firstly by comparing mean levels of beliefs e.g.
about controllability of diabetes between experimental
groups and secondly by a more formal mediation analysis
[28]. Within group analyses will be used to determine
fidelity to protocol and conformity to the theoretical
model, between group analyses will be used to assess
impact of the intervention on key variables proposed by
the theoretical model. Additional exploratory analysis
will include changes in behaviour in relation to perceived
threat and changes in perceived thereat from diabetes.
Economic evaluation
The economic evaluation will be on an intention-to-treat
basis. A cost-effectiveness/cost-utility analysis will be per-
formed in which the difference in effectiveness will be
compared to the difference in total costs between each
study intervention group, and the results will be expressed
as incremental cost-effectiveness ratios. Effectiveness will
be measured in terms of change in HbA1c, and modelled
for life years gained and quality adjusted life years gained.Page 6 of 8
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from the healthcare resource utilisation assessment using
published national average costs and tariff averages for
procedures to calculate costs. Mean values and 95% con-
fidence intervals will be reported for each component of
resource use and cost and for total costs and effectiveness.
Sensitivity analyses will be performed on all aspects of the
economic evaluation that are subject to uncertainty.
Discussion
This study will make an important contribution to the evi-
dence-base for the use of blood glucose self-monitoring in
non-insulin using patients with type 2 diabetes. It will
provide a robust estimate of overall effect of use of the
meters for self-testing alone and with a more intensive
programme to support people in using their test results
actively in self management of health related behaviours.
This trial will address two main problems associated with
previous trials. Firstly, the study is adequately powered to
identify a reduction in HbA1c of 0.5%, which is associated
with clinically important reductions in diabetic complica-
tions. Secondly, study participants allocated to the most
intensive group are explicitly supported in interpretation
of their study results in relation to lifestyle changes. This
is the first study in this field to use standardised delivery
of these interventions together with the other measures
supporting fidelity to protocol.
A further strength of the trial design is the inclusion of
measures that explore the extent to which the interven-
tions being used influences beliefs and behaviour. It will
be possible to test whether the interventions, especially
that based on the CSM, are successful in altering beliefs
about diabetes, and whether the interventions were deliv-
ered with fidelity to their theoretical basis. It will also be
possible to test whether differences in behaviour and
HbA1c between experimental groups are due to the inter-
ventions bringing about changes in beliefs, as proposed
by the CSM. Depending on the pattern of findings from
the mediation analysis, it will be possible to conclude
there is no mediation (none of the causal effect of inter-
vention on behaviour is transmitted by beliefs about dia-
betes), total mediation (all of the effect is transmitted by
beliefs) or partial mediation (part of the effect is transmit-
ted by beliefs and part is direct). This will provide infor-
mation about the extent to which the CSM can usefully
inform intervention content to change beliefs and
behaviours.
The trial is mainly generalisable to that group of patients
willing to be randomised to no self-testing. It will be lim-
ited in its ability to inform management of people who
are enthusiastic about regular meter use. Not only does
this group include people who have already been recom-
mended to use a meter by their doctor or nurse, but also
includes people who have obtained a meter in the absence
of medical advice. In health service terms, these are people
who are likely to obtain a meter whether or not they are
prescribed or offered one. A trial to address management
in this group would be more difficult because of difficul-
ties in identifying individuals who are both enthusiasts,
yet willing not to be exposed to the use of self-monitoring.
However, the detailed information about beliefs and the
pre-specified sub-group analyses will provide information
to inform design of future studies in this area by allowing
refinement of interventions and accurate estimates to
inform sample size calculations The detailed information
from blood glucose diaries and relation to outcomes will
also inform the refinement of training programmes and
data interpretation.
This trial has features of both a pragmatic and an explan-
atory trial [29]. The use of three parallel groups, delivery
of interventions according to protocol and extensive
measures along a causal pathway are characteristic of
phase III or explanatory trials. The use of a primary care
setting, comparison of three feasible health service strate-
gies, wide range of recruitment a long duration, and esti-
mation of costs are, however, more characteristic of a
pragmatic trial. This hybrid design, whilst answering a
health service question, will provide additional informa-
tion to guide future research. The extent to which the trial
is able to deliver data that informs both of these agendas
will inform design of trials of emerging health technolo-
gies where the opportunity to understand underlying
mechanisms may be lost in an effort to simplify protocol
design.
The results of this trial will be available in 2007.
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